Published in Invest Ophthalmol Vis Sci on August 01, 1990
Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates? Vaccine (2011) 1.07
Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol (1998) 0.94
Broadening the repertoire of functional herpes simplex virus type 1-specific CD8+ T cells reduces viral reactivation from latency in sensory ganglia. J Immunol (2013) 0.84
HSV-1 latent rabbits shed viral DNA into their saliva. Virol J (2012) 0.82
Bovine Herpes Virus 1 (BHV-1) and Herpes Simplex Virus Type 1 (HSV-1) Promote Survival of Latently Infected Sensory Neurons, in Part by Inhibiting Apoptosis. J Cell Death (2013) 0.79
Targeting herpetic keratitis by gene therapy. J Ophthalmol (2012) 0.76
Detection of latency-related viral RNAs in trigeminal ganglia of rabbits latently infected with herpes simplex virus type 1. J Virol (1987) 5.45
Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript. Science (2000) 3.51
Fine mapping of the latency-related gene of herpes simplex virus type 1: alternative splicing produces distinct latency-related RNAs containing open reading frames. J Virol (1988) 3.51
The latency-associated transcript gene of herpes simplex virus type 1 (HSV-1) is required for efficient in vivo spontaneous reactivation of HSV-1 from latency. J Virol (1994) 2.94
Activity of herpes simplex virus type 1 latency-associated transcript (LAT) promoter in neuron-derived cells: evidence for neuron specificity and for a large LAT transcript. J Virol (1990) 2.87
Sequence of the latency-related gene of herpes simplex virus type 1. Virology (1989) 2.29
Intracellular synthesis of measles virus-specified polypeptides. J Virol (1978) 2.21
Complete sequence of bluetongue virus L2 RNA that codes for the antigen recognized by neutralizing antibodies. J Virol (1985) 2.17
The spontaneous reactivation function of the herpes simplex virus type 1 LAT gene resides completely within the first 1.5 kilobases of the 8.3-kilobase primary transcript. J Virol (1996) 1.93
Fine mapping of the major latency-related RNA of herpes simplex virus type 1 in humans. J Gen Virol (1988) 1.89
The latency-associated transcript gene enhances establishment of herpes simplex virus type 1 latency in rabbits. J Virol (2000) 1.57
Region of herpes simplex virus type 1 latency-associated transcript sufficient for wild-type spontaneous reactivation promotes cell survival in tissue culture. J Virol (2001) 1.55
An avirulent ICP34.5 deletion mutant of herpes simplex virus type 1 is capable of in vivo spontaneous reactivation. J Virol (1995) 1.54
In vitro promoter activity associated with the latency-associated transcript gene of herpes simplex virus type 1. J Gen Virol (1989) 1.52
Immune response in subacute sclerosing panencephalitis: reduced antibody response to the matrix protein of measles virus. J Immunol (1979) 1.52
A 371-nucleotide region between the herpes simplex virus type 1 (HSV-1) LAT promoter and the 2-kilobase LAT is not essential for efficient spontaneous reactivation of latent HSV-1. J Virol (1996) 1.51
Identification of a major regulatory sequence in the latency associated transcript (LAT) promoter of herpes simplex virus type 1 (HSV-1). Virology (1991) 1.48
Differences between the intracellular polypeptides of measles and subacute sclerosing panencephalitis virus. Nature (1978) 1.41
A herpes simplex virus type 1 latency-associated transcript mutant with increased virulence and reduced spontaneous reactivation. J Virol (1999) 1.35
Measles and SSPE viruses: similarities and differences. Prog Med Virol (1982) 1.30
The region of the herpes simplex virus type 1 LAT gene that is colinear with the ICP34.5 gene is not involved in spontaneous reactivation. J Virol (1996) 1.25
Expression of seven herpes simplex virus type 1 glycoproteins (gB, gC, gD, gE, gG, gH, and gI): comparative protection against lethal challenge in mice. J Virol (1994) 1.23
Purification of measles virus and characterization of subviral components. J Virol (1979) 1.20
The effect of latency-associated transcript on the herpes simplex virus type 1 latency-reactivation phenotype is mouse strain-dependent. J Gen Virol (2001) 1.17
The complete sequence of bluetongue virus serotype 10 segment 3 and its predicted VP3 polypeptide compared with those of BTV serotype 17. Virus Res (1985) 1.16
The region of the herpes simplex virus type 1 LAT gene involved in spontaneous reactivation does not encode a functional protein. Virology (1998) 1.16
Expression of bluetongue virus group-specific antigen VP3 in insect cells by a baculovirus vector: its use for the detection of bluetongue virus antibodies. J Gen Virol (1987) 1.13
Molecular cloning and sequence analysis of the human parainfluenza 3 virus mRNA encoding the P and C proteins. Virology (1986) 1.12
Both CD4+ and CD8+ T cells are involved in protection against HSV-1 induced corneal scarring. Br J Ophthalmol (2000) 1.12
The role of natural killer cells in protection of mice against death and corneal scarring following ocular HSV-1 infection. Antiviral Res (2000) 1.11
Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins. Invest Ophthalmol Vis Sci (1995) 1.10
An improved method for cloning portions of the repeat regions of herpes simplex virus type 1. J Virol Methods (1994) 1.10
Three herpes simplex virus type 1 latency-associated transcript mutants with distinct and asymmetric effects on virulence in mice compared with rabbits. J Virol (2001) 1.09
Immunoselection of recombinant baculoviruses expressing high levels of biologically active herpes simplex virus type 1 glycoprotein D. Arch Virol (1991) 1.07
Cell surface expression of herpes simplex virus type 1 glycoprotein H in recombinant baculovirus-infected cells. Virology (1991) 1.07
Mapping herpes simplex virus type 1 latency-associated transcript sequences that protect from apoptosis mediated by a plasmid expressing caspase-8. J Neurovirol (2004) 1.06
Molecular cloning and sequence analysis of the human parainfluenza 3 virus RNA encoding the nucleocapsid protein. Virology (1986) 1.06
Measles virus-specified polypeptide synthesis in two persistently infected HeLa cell lines. J Virol (1979) 1.06
Expression of the first 811 nucleotides of the herpes simplex virus type 1 latency-associated transcript (LAT) partially restores wild-type spontaneous reactivation to a LAT-null mutant. Virology (1999) 1.02
The role of interleukin (IL)-2 and IL-4 in herpes simplex virus type 1 ocular replication and eye disease. J Infect Dis (1999) 1.01
Baculovirus-expressed glycoprotein E (gE) of herpes simplex virus type-1 (HSV-1) protects mice against lethal intraperitoneal and lethal ocular HSV-1 challenge. Virology (1992) 1.00
Immediate persistent infection by human parainfluenza virus 3: unique fusion properties of the persistently infected cells. J Gen Virol (1987) 1.00
Nucleotide sequence of RNA segment 7 and the predicted amino sequence of M1 and M2 proteins of FPV/Weybridge (H7N7) and WSN (H1N1) influenza viruses. Virus Res (1988) 1.00
Expression of herpes simplex virus type 1 glycoprotein B in insect cells. Initial analysis of its biochemical and immunological properties. Virus Res (1992) 0.99
A therapeutic vaccine that reduces recurrent herpes simplex virus type 1 corneal disease. Invest Ophthalmol Vis Sci (1998) 0.99
Vaccination of mice with herpes simplex virus type 1 glycoprotein D DNA produces low levels of protection against lethal HSV-1 challenge. Antiviral Res (1995) 0.99
Intracellular synthesis of human parainfluenza type 3 virus-specified polypeptides. J Virol (1985) 0.98
M protein instability and lack of H protein processing associated with nonproductive persistent infection of HeLa cells by measles virus. Virology (1985) 0.95
Recombinant herpes simplex virus type 1 expressing murine interleukin-4 is less virulent than wild-type virus in mice. J Virol (2001) 0.95
Local periocular vaccination protects against eye disease more effectively than systemic vaccination following primary ocular herpes simplex virus infection in rabbits. J Virol (1998) 0.94
Characterization of baculovirus-expressed herpes simplex virus type 1 glycoprotein K. J Virol (1994) 0.93
The role of neutralizing antibody and T-helper subtypes in protection and pathogenesis of vaccinated mice following ocular HSV-1 challenge. Immunology (1998) 0.92
Identical 371-base-pair deletion mutations in the LAT genes of herpes simplex virus type 1 McKrae and 17syn+ result in different in vivo reactivation phenotypes. J Virol (1999) 0.91
Baculovirus-expressed glycoprotein G of herpes simplex virus type 1 partially protects vaccinated mice against lethal HSV-1 challenge. Virology (1992) 0.90
The US5 open reading frame of herpes simplex virus type 1 does encode a glycoprotein (gJ). Intervirology (1998) 0.90
The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge. Immunology (1997) 0.90
Expression of herpes simplex virus type 1 glycoprotein I in baculovirus: preliminary biochemical characterization and protection studies. J Virol (1992) 0.90
Either a CD4(+)or CD8(+)T cell function is sufficient for clearance of infectious virus from trigeminal ganglia and establishment of herpes simplex virus type 1 latency in mice. Microb Pathog (1999) 0.89
The UL3 open reading frame of herpes simplex virus type 1 codes for a phosphoprotein. Virus Res (1996) 0.89
Human parainfluenza virus 3: purification and characterization of subviral components, viral proteins and viral RNA. Virus Res (1985) 0.89
Cytokeratin provides a specific marker for human arachnoid cells grown in vitro. Exp Cell Res (1983) 0.89
Biochemical characterization of soybean ovary growth from anthesis to abscission of aborting ovaries. Plant Physiol (1986) 0.89
Baculovirus expressed herpes simplex virus type 1 glycoprotein C protects mice from lethal HSV-1 infection. Antiviral Res (1992) 0.89
MHC-II but not MHC-I responses are required for vaccine-induced protection against ocular challenge with HSV-1. Curr Eye Res (1997) 0.88
Nonneutralizing antibody against the glycoprotein K of herpes simplex virus type-1 exacerbates herpes simplex virus type-1-induced corneal scarring in various virus-mouse strain combinations. Invest Ophthalmol Vis Sci (1997) 0.87
Vaccine therapy for ocular herpes simplex virus (HSV) infection: periocular vaccination reduces spontaneous ocular HSV type 1 shedding in latently infected rabbits. J Virol (1994) 0.86
Use of cytokine immunotherapy to block CNS demyelination induced by a recombinant HSV-1 expressing IL-2. Gene Ther (2011) 0.86
Molecular cloning and sequence analysis of the human parainfluenza 3 virus gene encoding the matrix protein. Virology (1987) 0.86
A herpes simplex virus type 1 mutant deleted for gamma34.5 and LAT kills glioma cells in vitro and is inhibited for in vivo reactivation. Cancer Gene Ther (2001) 0.85
Vaccination with herpes simplex virus type 1 glycoprotein K impairs clearance of virus from the trigeminal ganglia resulting in chronic infection. Virology (1996) 0.85
A simple method for increased recovery of purified paramyxovirus virions. J Virol Methods (1985) 0.84